Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Version: 20 July 1993
Length: 18 pages
Data source: Field research
Abstract
Genzyme Corp's financing history is unusual compared to most biotech companies. This case presents the sequence of financings employed by Genzyme, along with the product - market and corporate-development strategies adopted by Henri Termeer, Genzyme's CEO. As such, the case permits students to evaluate the sequence of financings as a 'program' rather than a series of unrelated deals and to consider them in light of the business strategy.
Location:
Industry:
Size:
USD220 million revenues
Other setting(s):
1983-1993
Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Length: 16 pages
About
Abstract
Genzyme Corp's financing history is unusual compared to most biotech companies. This case presents the sequence of financings employed by Genzyme, along with the product - market and corporate-development strategies adopted by Henri Termeer, Genzyme's CEO. As such, the case permits students to evaluate the sequence of financings as a 'program' rather than a series of unrelated deals and to consider them in light of the business strategy.
Settings
Location:
Industry:
Size:
USD220 million revenues
Other setting(s):
1983-1993
Related
Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Length: 16 pages